Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ny-eso-1 peptide-pulsed dendritic cells
- Development stage
- Unknown
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
NY-ESO-1 peptide-pulsed dendritic cells are an autologous cellular immunotherapy and cancer vaccine designed to elicit a targeted immune response against tumors expressing the New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen. The process involves harvesting a patient's monocytes via leukapheresis, differentiating them into dendritic cells (DCs) ex vivo, and "pulsing" or loading them with specific HLA-restricted peptides derived from the NY-ESO-1 protein. NY-ESO-1 is a cancer-testis antigen that is highly expressed in various malignancies—including melanoma, synovial sarcoma, and ovarian cancer—but is absent in normal adult tissues except for the testis, making it a highly specific target. Once re-infused into the patient, these mature, antigen-presenting DCs migrate to the lymph nodes where they activate and expand NY-ESO-1-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T cells to recognize and destroy tumor cells.
- Other names
- NY-ESO-1 pulsed DC vaccineNY-ESO1 pulsed DC vaccineNY-ESO 1 pulsed DC vaccineNY-ESO-1 peptide-loaded dendritic cellsNY-ESO1 peptide-loaded dendritic cellsNY-ESO 1 peptide-loaded dendritic cellsNY-ESO-1-pulsed autologous dendritic cell vaccineNY-ESO1-pulsed autologous dendritic cell vaccineNY-ESO 1-pulsed autologous dendritic cell vaccine
02
Targets
New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide-HLA complex
Beyond the preview
Go deeper on ny-eso-1 peptide-pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ny-eso-1 peptide-pulsed dendritic cells.